Immunity to α-Gal: Toward a Single-Antigen Pan-Vaccine To Control Major Infectious Diseases
Status PubMed-not-MEDLINE Language English Country United States Media print-electronic
Document type News
PubMed
29202015
PubMed Central
PMC5704288
DOI
10.1021/acscentsci.7b00517
Knihovny.cz E-resources
Faculty of Science University of South Bohemia České Budějovice 37005 Czech Republic
SaBio Instituto de Investigación de Recursos Cinegéticos IREC CSIC UCLM JCCM 13005 Ciudad Real Spain
See more in PubMed
WHO. Vector-borne diseases: Fact sheet No. 387 2014; World Health Organization: Geneva, 2017. http://www.who.int/mediacentre/factsheets/fs387/en/ (accessed Oct 9, 2017).
WHO. A global brief on vector-borne diseases; World Health Organization: Geneva, 2014. Available at http://apps.who.int/iris/bitstream/10665/111008/1/WHO_DCO_WHD_2014.1_eng.pdf?ua=1 (accessed Oct 9, 2017).
WHO. Tuberculosis Fact sheet No. 104 2015; World Health Organization: 2017. Available at http://www.who.int/mediacentre/factsheets/fs104/en/ (accessed July 2, 2017).
Yilmaz B.; Portugal S.; Tran T. M.; Gozzelino R.; Ramos S.; Gomes J.; Regalado A.; Cowan P. J.; d’Apice A. J.; Chong A. S.; Doumbo O. K.; Traore B.; Crompton P. D.; Silveira H.; Soares M. P. Gut microbiota elicits a protective immune response against malaria transmission. Cell 2014, 159, 1277–1289. 10.1016/j.cell.2014.10.053. PubMed DOI PMC
Cabezas-Cruz A.; Valdés J. J.; de la Fuente J. Control of vector-borne infectious diseases by human immunity against α-Gal. Expert Rev. Vaccines 2016, 15, 953–955. 10.1080/14760584.2016.1181547. PubMed DOI
Moura A. P. V.; Santos L. C. B.; Brito C. R. N.; Valencia E.; Junqueira C.; Filho A. A. P.; Sant’Anna M. R. V.; Gontijo N. F.; Bartholomeu D. C.; Fujiwara R. T.; Gazzinelli R. T.; McKay C. S.; Sanhueza C. A.; Finn M. G.; Marques A. F. Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania Infection. ACS Cent. Sci. 2017, 3, 1026–1031. 10.1021/acscentsci.7b00311. PubMed DOI PMC
Almeida I. C.; Milani S. R.; Gorin P. A.; Travassos L. R. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies. J. Immunol. 1991, 146, 2394–2400. PubMed
Galili U.; Mandrell R. E.; Hamadeh R. M.; Shohet S. B.; Griffiss J. M. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect. Immun. 1988, 56, 1730–1737. PubMed PMC
Yooseph S.; Kirkness E. F.; Tran T. M.; Harkins D. M.; Jones M. B.; Torralba M. G.; O’Connell E.; Nutman T. B.; Doumbo S.; Doumbo O. K.; Traore B.; Crompton P. D.; Nelson K. E. Stool microbiota composition is associated with the prospective risk of Plasmodium falciparum infection. BMC Genomics 2015, 16, 631.10.1186/s12864-015-1819-3. PubMed DOI PMC
Cabezas-Cruz A.; Mateos-Hernández L.; Alberdi P.; Villar M.; Riveau G.; Hermann E.; Schacht A. M.; Khalife J.; Correia-Neves M.; Gortazar C.; de la Fuente J. Effect of blood type on anti-α-Gal immunity and the incidence of infectious diseases. Exp. Mol. Med. 2017, 49, e301.10.1038/emm.2016.164. PubMed DOI PMC
Zamze S. E.; Ashford D. A.; Wooten E. W.; Rademacher T. W.; Dwek R. A. Structural characterization of the asparagine-linked oligosaccharides from Trypanosoma brucei type II and type III variant surface glycoproteins. J. Biol. Chem. 1991, 266, 20244–20261. PubMed
Couto A. S.; Gonçalves M. F.; Colli W.; de Lederkremer R. M. The N-linked carbohydrate chain of the 85-kilodalton glycoprotein from Trypanosoma cruzi trypomastigotes contains sialyl, fucosyl and galactosyl (alpha 1–3)galactose units. Mol. Biochem. Parasitol. 1990, 39, 101–7. 10.1016/0166-6851(90)90012-B. PubMed DOI
Novel targets and strategies to combat borreliosis
Tick Bites Induce Anti-α-Gal Antibodies in Dogs
Immunity to α-Gal: The Opportunity for Malaria and Tuberculosis Control
